1. Home
  2. AGIO vs ENVX Comparison

AGIO vs ENVX Comparison

Compare AGIO & ENVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • ENVX
  • Stock Information
  • Founded
  • AGIO 2007
  • ENVX 2006
  • Country
  • AGIO United States
  • ENVX United States
  • Employees
  • AGIO N/A
  • ENVX N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • ENVX Industrial Machinery/Components
  • Sector
  • AGIO Health Care
  • ENVX Miscellaneous
  • Exchange
  • AGIO Nasdaq
  • ENVX Nasdaq
  • Market Cap
  • AGIO 1.4B
  • ENVX 1.5B
  • IPO Year
  • AGIO 2013
  • ENVX N/A
  • Fundamental
  • Price
  • AGIO $39.23
  • ENVX $14.65
  • Analyst Decision
  • AGIO Buy
  • ENVX Strong Buy
  • Analyst Count
  • AGIO 6
  • ENVX 11
  • Target Price
  • AGIO $58.60
  • ENVX $18.45
  • AVG Volume (30 Days)
  • AGIO 615.0K
  • ENVX 8.0M
  • Earning Date
  • AGIO 07-31-2025
  • ENVX 07-30-2025
  • Dividend Yield
  • AGIO N/A
  • ENVX N/A
  • EPS Growth
  • AGIO N/A
  • ENVX N/A
  • EPS
  • AGIO 11.45
  • ENVX N/A
  • Revenue
  • AGIO $37,035,000.00
  • ENVX $22,900,000.00
  • Revenue This Year
  • AGIO $22.30
  • ENVX $47.91
  • Revenue Next Year
  • AGIO $219.19
  • ENVX $249.62
  • P/E Ratio
  • AGIO $3.39
  • ENVX N/A
  • Revenue Growth
  • AGIO 25.96
  • ENVX 77.59
  • 52 Week Low
  • AGIO $23.42
  • ENVX $5.27
  • 52 Week High
  • AGIO $62.58
  • ENVX $18.68
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 70.51
  • ENVX 82.61
  • Support Level
  • AGIO $34.60
  • ENVX $13.34
  • Resistance Level
  • AGIO $40.06
  • ENVX $14.50
  • Average True Range (ATR)
  • AGIO 1.45
  • ENVX 0.96
  • MACD
  • AGIO 0.43
  • ENVX 0.43
  • Stochastic Oscillator
  • AGIO 88.98
  • ENVX 97.16

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About ENVX Enovix Corporation

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.

Share on Social Networks: